Management of fingolimod-associated macular edema

JAMA Ophthalmol. 2013 May;131(5):694-6. doi: 10.1001/jamaophthalmol.2013.47.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Administration, Topical
  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Dexamethasone / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Fingolimod Hydrochloride
  • Fluorescein Angiography
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Intraocular Pressure
  • Ketorolac Tromethamine / therapeutic use*
  • Macular Edema / chemically induced*
  • Macular Edema / diagnosis
  • Macular Edema / drug therapy*
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Propylene Glycols / adverse effects*
  • Sphingosine / adverse effects
  • Sphingosine / analogs & derivatives*
  • Tomography, Optical Coherence
  • Treatment Outcome
  • Visual Acuity

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Glucocorticoids
  • Immunosuppressive Agents
  • Propylene Glycols
  • Ketorolac Tromethamine
  • Dexamethasone
  • Fingolimod Hydrochloride
  • Sphingosine